These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 22793066)

  • 61. A Single-Center Experience of the Optimal Initial Immunosuppressive Strategy for Preventing Early Acute Cellular Rejection in Orthotopic Heart Transplantation Associated With Renal Dysfunction.
    Mundisugih J; Fernando H; Bergin P; Hare J; Kaye D; Leet A; McGiffin D; Taylor AJ
    Prog Transplant; 2019 Dec; 29(4):327-334. PubMed ID: 31476958
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study.
    Ganschow R; Ericzon BG; Dhawan A; Sharif K; Martzloff ED; Rauer B; Ng J; Lopez P
    Pediatr Transplant; 2017 Nov; 21(7):. PubMed ID: 28714558
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Basiliximab and heart transplantation in Hispanics: the experience in Puerto Rico.
    Banchs HL; Carro Jiménez EJ; González V; González Cancel IF; Quintana C; Calderón R; Altieri PI; Rivera C
    Bol Asoc Med P R; 2007; 99(3):191-6. PubMed ID: 19610574
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A safe immunosuppressive protocol in adult-to-adult living related liver transplantation.
    Gruttadauria S; Cintorino D; Piazza T; Mandala L; Doffria E; Musumeci A; Di Trapani G; Arcadipane A; Scianna G; Spada M; Verzaro R; Volpes R; Vizzini G; Palazzo U; Minervini M; Marsh JW; Marcos A; Gridelli B
    Transplant Proc; 2006 May; 38(4):1106-8. PubMed ID: 16757278
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
    Hausen B; Gummert J; Berry GJ; Christians U; Serkova N; Ikonen T; Hook L; Legay F; Schuler W; Schreier MH; Morris RE
    Transplantation; 2000 Feb; 69(4):488-96. PubMed ID: 10708100
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.
    de Sandes-Freitas TV; Felipe CR; de Franco MF; Tedesco-Silva H; Medina-Pestana JO
    Int Urol Nephrol; 2013 Apr; 45(2):537-46. PubMed ID: 23054318
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
    Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
    Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation.
    Arora N; McKiernan PJ; Beath SV; deVille de Goyet J; Kelly DA
    Pediatr Transplant; 2002 Jun; 6(3):214-8. PubMed ID: 12100505
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Basiliximab does not reduce the early rejection incidence in high-risk kidney recipients under tacrolimus-based immunosuppression.
    Cho WH; Lee HJ; Kim HT; Hwang EA; Han SY; Park SB; Kim HC
    Transplant Proc; 2008 Sep; 40(7):2234-6. PubMed ID: 18790201
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy.
    Krystufkova E; Sekerkova A; Striz I; Brabcova I; Girmanova E; Viklicky O
    Nephrol Dial Transplant; 2012 Jun; 27(6):2576-82. PubMed ID: 22167587
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.
    Neuhaus P; Clavien PA; Kittur D; Salizzoni M; Rimola A; Abeywickrama K; Ortmann E; Chodoff L; Hall M; Korn A; Nashan B;
    Liver Transpl; 2002 Feb; 8(2):132-42. PubMed ID: 11862589
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
    N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
    Tojimbara T; Sato S; Koyama I; Nanmoku K; Sekijima M; Tonsyo M; Kai K; Kato Y; Urashima Y; Nakajima I; Fuchinoue S; Teraoka S
    Transplant Proc; 2005 Mar; 37(2):895-8. PubMed ID: 15848568
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Induction with basiliximab in renal transplantation.
    Ferrer F; Machado S; Alves R; Macário F; Bastos C; Roseiro A; Mota A
    Transplant Proc; 2010 Mar; 42(2):467-70. PubMed ID: 20304166
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The role of basiliximab induction therapy in adult-to-adult living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single-center series.
    Viganò J; Gruttadauria S; Mandalà L; Petridis I; Cintorino D; Li Petri S; Varotti G; Minervini M; Volpes R; Biondo D; Vizzini G; Marsh WJ; Marcos A; Gridelli B
    Transplant Proc; 2008; 40(6):1953-5. PubMed ID: 18675099
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Basiliximab: efficacy and safety evaluation in kidney transplantation.
    Ponticelli C
    Expert Opin Drug Saf; 2014 Mar; 13(3):373-81. PubMed ID: 24266670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.